title: Clinical associations and prognostic significance of serum anti-p53 antibodies in Thai patients with hepatocellular carcinoma.
abstract: Mutations of the p53 gene have been reported to be of prognostic significance in hepatocellular carcinoma (HCC). However, the clinical associations and prognostic value of anti-p53 antibodies, known to be products of the host immune response to these mutations, have been controversial. Serum anti-p53 antibodies were measured in 121 Thai patients diagnosed with HCC using a specific enzyme-linked immunosorbent assay (ELISA) kit. The clinical/pathological characteristics of the patients were compared with respect to the presence of serum anti-p53 antibodies. Cox regression analysis was performed to assess factor interaction and association with survival. Anti-p53 antibodies were detected in 13.2% (16 of 121) of our patients. There were no differences between groups with regard to age, sex, viral markers (HBsAg or anti-HCV), severity of liver disease and tumor advancement. The median survival rates for patients positive and negative for anti-p53 antibodies were 4.0 and 3.0 months, respectively (p = 0.443, by log-rank test). Multivariate analysis demonstrated that an advanced Okuda stage, lack of therapy and presence of portal vein thrombosis were independent factors related to the prognosis of the patients. Nonetheless, the presence of anti-p53 antibodies did not constitute a predictive variable associated with a poorer prognosis. Serum assay of anti-p53 antibodies, although rapid and easily performed, may not be suitable as an alternative to molecular detection of mutations in assessing tumor advancement and prognosis of patients with HCC.
authors.affiliation: Department of Biochemistry, Chulalongkom University & Hospital, Bangkok, Thailand.
authors.forename: P
authors.initials: P
authors.lastname: Tangkijvanich
authors.forename: A
authors.initials: A
authors.lastname: Janchai
authors.forename: N
authors.initials: N
authors.lastname: Charuruks
authors.forename: P
authors.initials: P
authors.lastname: Kullavanijaya
authors.forename: A
authors.initials: A
authors.lastname: Theamboonlers
authors.forename: P
authors.initials: P
authors.lastname: Hirsch
authors.forename: Y
authors.initials: Y
authors.lastname: Poovorawan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000912:Antibodies, Neoplasm / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000276:immunology* / Q000401:mortality* / Q000473:pathology; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000276:immunology* / Q000401:mortality* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011379:Prognosis; D016016:Proportional Hazards Models; D015996:Survival Rate; D013785:Thailand / Q000453:epidemiology; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
chemical_list: D000912:Antibodies, Neoplasm; D016159:Tumor Suppressor Protein p53